company background image
PTN

Palatin Technologies NYSEAM:PTN Stock Report

Last Price

US$0.32

Market Cap

US$74.8m

7D

19.5%

1Y

-28.9%

Updated

16 Aug, 2022

Data

Company Financials +
PTN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PTN Stock Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.

Palatin Technologies, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Palatin Technologies
Historical stock prices
Current Share PriceUS$0.32
52 Week HighUS$0.96
52 Week LowUS$0.25
Beta1.04
1 Month Change18.60%
3 Month Change-10.76%
1 Year Change-28.94%
3 Year Change-64.74%
5 Year Change-17.30%
Change since IPO-99.99%

Recent News & Updates

Shareholder Returns

PTNUS BiotechsUS Market
7D19.5%1.4%3.6%
1Y-28.9%-19.6%-9.6%

Return vs Industry: PTN underperformed the US Biotechs industry which returned -19.6% over the past year.

Return vs Market: PTN underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is PTN's price volatile compared to industry and market?
PTN volatility
PTN Average Weekly Movement10.1%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: PTN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: PTN's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198626Carl Spanahttps://palatin.com

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases.

Palatin Technologies, Inc. Fundamentals Summary

How do Palatin Technologies's earnings and revenue compare to its market cap?
PTN fundamental statistics
Market CapUS$74.77m
Earnings (TTM)-US$37.36m
Revenue (TTM)US$872.91k

85.8x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PTN income statement (TTM)
RevenueUS$872.91k
Cost of RevenueUS$17.54m
Gross Profit-US$16.67m
Other ExpensesUS$20.70m
Earnings-US$37.36m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.16
Gross Margin-1,909.46%
Net Profit Margin-4,280.50%
Debt/Equity Ratio0%

How did PTN perform over the long term?

See historical performance and comparison